Dexcom following ADC

Dexcom is 3 years behind ADC - their G7 CGM is not functional; they cant scale production until 2023 - so losing market share to ADC.

Ironically, ADC is failing in 2021 with low revenues, so Dexcom s chasing a losing strategy

 

Dexcom claims $1.95B revenue in 2020 -most of that is bogus; Dexcom is being run (into the ground by a bunch of bean counters and ex-Abbott people).

SEC is investigating wild 25% swings in stock price at each quarter end

 

Please ... Dexcom is barely at $600MM provable revenue for 2020 - rest is smoke & mirrors - QB is good at cooking up revenues out of thin air

 

SEC probe is coming soon - QB, Jereme & gang will soon be exposed - Dex is a financial fraud in the making.

 

Look its simple - Dexcom thought they could out-scale ADC - no way can they match Abbott's scale and so are heading for a collapse

 

Theranos revisted??

 

Dexcom is not as bad as Theranos - there are real revenues and profits at Dexcom; just not what is being reproted by QB; numbers are being inflated 3-fold. Also, Dexcom is suing Abbott for IP Theft - but Dexcom is no match for Abbott's corporate legal might

 

Dexcom is on its way down - G7 is non-functional (2 year launch delay), G6 has significant quality challenges, talent is heading out the door faster than they can replenish ... but the VP levels are raking in short-vested RSUs

 

haha! Not quita that level of fraud, but surely a pump-and-dump stock boiler room. No way Dx is selling $2B worth of G6 CGMs - fabricated sales & shipment numbers (new fraud EVP of Ops Barry R is a conman extraordinaire)

 

Barry R? Ha ha ha - he was exited from Abbott and Abbvie - he is a pompus racist jerk - he talked Dx into paying him a fortune $~$4M in RSUs) - people are quitting in droces under the 'Barry treatment'

 

Oh my - Barry is the most hated EVP in Dx - and customers loathe him too - under his management, supply chain service levels have dropped below 65% (lowest in Dx history) - Walgreens is threatening to pull G6 and go with Libre instead

 

Meanwhile, Quentin (QB) the former CFO & COO of Dexcom ran away to join a small med-tech co: he escaped with $$$MIllions isn RSUs (with accelerated vesting) before the SEC could close in on him

And yes, the SEC investigation is supposedly ongoing - some emplyees have been getting calls from law firms seeking Dx whitsleblowers

 

Remember the lawsuit that DX has on Abbott. ADC likely will stop filling vacant territories.

 

Dexcom CFO Quentin B quickly escaped and left the company before the SEC investigation progressed enough to nab him, leaving behind an inflated unsustainable stock price and suspect financials; stock price dropped from over $600 down to $360 in just a few months - Ouch!

 

And the G7 is just a figment of DexCom's imagination. They have been talking about if for over 6 years while FSL has been ramping up to 4M users and the FSL 3 has EU approval and FDA submission.

 

I believe G7 has been conditionally approved by FDA; although Jake L (Head of R & D) and Barry R (EVP Ops) are both well aware of a critical moisture leak issue that exposes users to mold infections and incorrect readings. Terrified that Dx will unleash this malfunctioning device on unsuspecting patients ...

 

How would one know of a conditional approval? Abbott got the EU mark on Libre 3 almost a year and a half ago. It had a limited release in the EU (Germany). One poster suggested that the Libre 2 is making so much money that Abbott is not rushing the Libre 3 roll out in the EU. Also, the release in Germany gives time to discover and work out any technical and production issues. In the Q4 conference call Ford said the full rollout for Libre 3 will be in Q2 of this year. I am not aware of the FDA approval status of the FSL 3. DX needs to be careful of rushing the rollout of the F7....could have a shit storm of problems like the FSL1 did back in 2014.

 

info available via FDA's FOIA electronic reading rm (and some insider info as well); Dx is big in the San Diego biotech/med device niche, and the conditional approval info has been leaked deliberately by Dx finance to shore up stock price

 

Approval is for limited use in hospitals for ICU use for COVID patients and for expectant moms fearing gestational diabetes; also, Google's Verily grabbed a few billion of Dx shares and Verily's CFO (Deepak A) is pressuring Dx to keep up the share price with 'managed release' of G7 info into the public domain - this is a common trick used by tech companies with no revenues to boost their stock price .

Also, Verily is a big investor in Dx and is preparing for an IPO of their own - so leaking positive info is a clever (but unethical/illegal) way to shore up Dx stock price

 

Whoa! Barry R landed at Dexcom? Word is, he was kicked out of Abbott and then Abbvie years ago: hear multiple HR complaints against him. In the AbbVie Puerto Rico site, hear he was caught harassing young women on the mfg floor, and their BFs threatened to 'get him' in the parking lot: he was quickly exited 'for his own safety'!